HR 1199 United States House · 118th Congress

Facilitating Innovative Nuclear Diagnostics Act of 2023

This bill requires Medicare to pay separately for certain high-cost diagnostic drugs used in nuclear imaging (like those for cancer detection) starting in 2024. It applies to drugs with a daily cost of $500 or more (adjusted annually), ensuring they are not bundled with other services. Payments will be based on either the drug's average sales price or wholesale cost, with adjustments to keep overall Medicare spending unchanged. This directly affects Medicare Part B providers (hospitals, clinics) and beneficiaries receiving these specific diagnostic treatments.

Issues: ✓ Healthcare

Sub-Topics: Medicare

Bill status in committee 1 of 4 stages cleared

Introduction

Feb 2023

Committee Review

Floor Vote

President

Introduced Feb 27, 2023 Last action May 16, 2024

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

May 16, 2024

Lower · Passed

Forwarded by Subcommittee to Full Committee by Voice Vote.

lower

May 16, 2024

Lower · Passed

Subcommittee Consideration and Mark-up Session Held

lower

Mar 10, 2023

Committee

Referred to the Subcommittee on Health.

lower

Feb 27, 2023

Committee

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

lower

Feb 27, 2023

Introduced

Introduced in House

lower

1 primary · 47 co-sponsors